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Abstract
Background: In patients with non- alcoholic fatty liver disease (NAFLD), the impact of the 
severity of steatosis and inflammatory activity on the accuracy of liver stiffness measure-
ment (LSM) by transient elastography (TE) and by two- dimensional shear wave elastog-
raphy (2D- SWE) in staging liver fibrosis is still debated and scarce. We aimed to focus on 
this aspect.
Methods: We prospectively studied 104 patients requiring biopsy for the assessment 
of NAFLD. We used ordinary least squares regression to test for differences in the as-
sociation between fibrosis and LSM by TE and 2D- SWE when other factors (steatosis 
and inflammatory activity) are considered.
Results: Among 104 patients, 102 had reliable LSM by TE, and 88 had valid LSM by 2D- 
SWE. The association between fibrosis based on histology and LSM was significantly 
stronger when 2D- SWE assessed LSM compared to TE (Spearman's correlation coefficient 
of .71; P < .001 vs .51, P < .001; Z = 2.21, P = .027). Inflammatory activity was an independ-
ent predictor of LSM by TE but not of LSM by 2D- SWE. After controlling for fibrosis, age, 
sex and body mass index, the inflammatory activity and the interaction between inflamma-
tory activity and fibrosis independently explained 11% and 13% of variance in LSM by TE 
respectively. Steatosis did not affect the association of fibrosis and LSM by either method.
Conclusion: Inflammatory activity on histology significantly affects LSM by TE, but 
not LSM by 2D- SWE in NAFLD. LSM by 2D- SWE reflects liver fibrosis more accu-
rately than LSM by TE. Furthermore, the severity of steatosis on histology did not 
influence the association of LSM and fibrosis by either elastography method.
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Fibroscan, fibrosis, liver stiffness measurement, NASH, non- invasive test
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1  |  INTRODUC TION
Liver fibrosis is the most important prognostic factor in patients with 
non- alcoholic fatty liver disease (NAFLD).1 Since NAFLD is rapidly in-
creasing and is already the most common cause of chronic liver disease 
worldwide2,3 and one of the main indications for liver transplanta-
tion,4,5 reliable methods to stage liver fibrosis in NAFLD are an urgent 
need in clinical practice. Liver biopsy remains the reference standard 
to characterize non- alcoholic steatohepatitis (NASH).6 Nevertheless, 
liver biopsy is an invasive and expensive procedure associated with pa-
tient discomfort and sampling variability.7,8 Elastography techniques, 
such as transient elastography (TE) and two- dimensional shear wave 
elastography (2D- SWE), provide a physical measure of liver stiffness 
which is closely related to fibrosis in chronic liver disease,9 and have 
emerged as an alternative to liver biopsy.
Although TE has been validated in NAFLD as a method to identify 
and stage fibrosis, it has been shown that steatosis and inflammatory 
activity might influence the accuracy of liver stiffness measurements 
(LSM) to predict fibrosis.9 However, the data regarding the impact 
of steatosis on LSM are still controversial. Some studies show no 
association,10- 12 one study showed that severe steatosis leads to an 
overestimation of liver fibrosis by LSM assessed using TE,13 and an-
other one showed that steatosis leads to an underestimation of liver 
fibrosis by LSM assessed by TE.14 To date, only one study evaluated 
the influence of steatosis and inflammation on LSM using 2D- SWE 
in NAFLD,15 and no head- to- head study compared TE and 2D- SWE 
vs histology with the aim of addressing which of the two methods is 
mostly influenced by confounders (steatosis and inflammation).
This study aimed to assess whether histological steatosis and in-
flammatory activity in NAFLD patients affects the accuracy of LSM 
by two different ultrasound elastography methods (TE and 2D- SWE) 
in predicting fibrosis.
2  |  PATIENTS AND METHODS
2.1  |  Study population
We prospectively included consecutive adult patients with NAFLD 
who underwent liver biopsy from August 2018 through September 
2020 who had LSM performed using TE and 2D- SWE within 
2 months from liver biopsy at an academic tertiary centre. Exclusion 
criteria were as follows: liver disease of other aetiology (chronic hep-
atitis B or C, autoimmune hepatitis, primary biliary cholangitis, pri-
mary sclerosing cholangitis, genetic hemochromatosis, drug- induced 
hepatotoxicity, a- 1 antitrypsin deficiency, Wilson's disease, etc); ex-
posure to drugs that can cause secondary NAFLD (corticosteroids, 
amiodarone and tamoxifen); significant alcohol consumption (>3 
standard drinks/day in men and >2 drinks/day in women, or binge 
drinking defined as >5 standard drinks in men and >4 in women over 
a 2- hour period)3; ALT >5 times the upper limit of normality; and 
refusal of consent to further use of personal health- related data for 
research.
The study was performed according to the principles of the 
Declaration of Helsinki, and approval was obtained from the local 
ethics committee (KEK BE 2018- 00487).
2.2  |  Clinical and laboratory assessment
Demographic, clinical, anthropometric and laboratory data were col-
lected at the time of the biopsy. Obesity was defined as body mass 
index (BMI) ≥30 kg/m2. Diabetes mellitus was defined as a fasting 
glycaemia ≥7 mmol/L or an HbA1c ≥6.5%, or current antidiabetic 
treatment. The presence of arterial hypertension and dyslipidaemia 
was recorded from the clinical charts.
2.3  |  LSM by transient elastography (TE)
Transient elastography (TE 502 Touch; Echosens, Paris, France) 
provided with M and XL probe was used to assess LSM, following 
the EASL- ALEH clinical practice guidelines (M probe in patients 
with BMI <30 kg/m2 and XL probe in obese patients and/or skin- 
to- capsule distance ≥25 mm). Measurements were performed in a 
fasting state during a routine visit at our hepatology outpatient facil-
ity. Only patients with 10 valid measurements were included in the 
study. IQR/M values ≥.30 were considered unreliable; no valid shots 
were considered as failures of the technique.
2.4  |  LSM by two- dimensional shear wave 
elastography
LSM by 2D- SWE was performed using the Aixplorer ultrasound 
system (SuperSonic Imagine SA, Aix- en- Provence, France). 
Patients were placed in a supine position, with the right arm in 
extension. The operator selected a region of the right lobe of the 
Key points
In patients with non- alcoholic fatty liver disease (NAFLD), 
the impact of steatosis and inflammatory activity on the 
accuracy of liver stiffness measurement is still debated. 
Therefore, we compared two non- invasive tests, transient 
elastography (Fibroscan®) and two- dimensional shear 
wave elastography (2D- SWE), in this population. We found 
that steatosis on histology did not affect liver stiffness by 
Fibroscan and 2D- SWE. Whereas the inflammatory activ-
ity significantly affects liver stiffness by Fibroscan but not 
by 2D- SWE. Furthermore, liver stiffness by 2D- SWE was 
better correlated with fibrosis stage. Thus, liver stiffness 
using 2D- SWE appears to reflect liver fibrosis more accu-
rately than Fibroscan in this population of NAFLD patients.
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liver with good spatial resolution for B- mode ultrasound imaging, 
free of large vascular structures and at least 15 mm below the 
capsule through a right intercostal space, and during breath hold 
activated 2D- SWE. Once a colour map with complete and homo-
geneous filling was obtained in the assessment area, a region of 
interest 15 mm in diameter was positioned in the centre of the 
colour map to measure stiffness using the Q box tool. We obtained 
three successful and valid measurements for each patient and 
used the mean value and the standard deviation of these meas-
urements as liver stiffness measure.16 Variability (SD) over 30% 
of the average liver stiffness value was considered as unreliable 
measurement.17 When the operator obtained little or no signal in 
the region of interest for all acquisitions, the measurements were 
defined as failures.
2.5  |  Histological assessment
Liver biopsies were assessed by one experienced pathologist. 
NAFLD severity was scored according to the SAF scoring system6 
that evaluates individually the grade of steatosis, activity and fi-
brosis. The steatosis grade was classified by the percentage of 
hepatocytes containing large- and medium- sized intracytoplasmic 
lipid droplets, on a scale of 0- 3 (0: <5%; 1: 5%- 33%; 2: 34%- 66%; 
and 3: >67%). The grade of inflammatory activity was rated from 
A0 to A4 by addition of grades of ballooning and lobular inflam-
mation, each graded from 0 to 2. Ballooning of hepatocytes was 
defined as the presence of hepatocyte clusters with a round 
shaped and pale cytoplasm (0: normal hepatocytes; 1: ballooning 
but normal size; and 2: ballooning with at least one enlarged bal-
looned hepatocyte). Lobular inflammation was defined as a focus 
of two or more inflammatory cells within the lobule organized 
either as microgranulomas or located within the sinusoids. Foci 
were counted at 20× magnification (grade 0: none; 1: ≤2 foci per 
lobule; and 2: >2 foci per lobule). The stage of fibrosis (F, from 
F0 to F4), was assessed according to the NASH Clinical Research 
Network staging system, with the single modification of pooling 
the three substages (1a, 1b and 1c) into a single F1 score. The di-
agnosis of NASH had >5% steatosis in hepatocytes and a grade of 
activity A ≥ 2.6,18 Moreover, the NAFLD activity score (NAS) was 
calculated. NAS is the unweighted sum of steatosis grade, lobular 
inflammation and ballooning, ranging from 0 to 8 according to the 
grades of steatosis (0- 3), lobular inflammation (0- 3) and hepatocel-
lular ballooning (0- 2).19 Interpretability for liver biopsy was based 
on the standard criteria of length, number of portal tracts (>10) 
and lack of major fragmentation.
2.6  |  Statistical analysis
Continuous variables are described as mean ± standard deviation, 
categorical variables as a number of cases (percentage). These de-
scriptive statistics are provided for the complete group (104 patients) 
and the subgroups with valid LSM by TE and by 2D- SWE. The sub-
groups of patients with and without valid SWE were compared using 
Welch's t- test where parametric assumptions are adequate. For or-
dinal variables, Wilcoxon's rank- sum test was used. Categorical vari-
ables were compared using the chi- squared test. Missing values on 
all predictor variables were handled using Multiple Imputation by 
Chained Equations with M = 20 imputations. The two non- invasive 
tests, LSM by TE and 2D- SWE, were not used as predictors when 
creating imputations for other variables and were not imputed them-
selves. Bivariate associations between patient demographic char-
acteristics, laboratory and liver histology parameter, and the two 
non- invasive tests, LSM by TE and LSM by 2D- SWE, were calculated 
using pairwise Spearman's correlations on multiply imputed data.
We performed a model comparison against the baseline model 
with fibrosis stage on Natural log (ln) LSM by TE and ln LSM by 2D- 
SWE. Covariates as well as their interactions with fibrosis stage were 
added to the baseline model one- by- one. The extended models 
were compared to the baseline models using an F- test to determine 
whether the addition of the covariate would add explained variance 
to the baseline model. All model comparisons were adjusted for mul-
tiple testing using the method by Holm. Ordinal variables were coded 
as treatment contrasts. Possible main effects or interactions of the 
covariate were then only further examined if the model explained 
significantly more variance than the baseline model. In addition, one 
more complex model was calculated for LSM by TE, which included 
patient characteristics as control variables as well as all significant 
covariates from the prior analyses. All reported P- values are two- 
sided and values <.05 were considered statistically significant. All 
confidence intervals are at the 95% level. Statistical analyses were 
conducted using R open- source statistical software, version 4.0.3.
3  |  RESULTS
3.1  |  Characteristics of the study population
One hundred and four patients undergoing liver biopsy to grade and 
stage NAFLD were evaluated using liver histology, relevant labora-
tory parameters and LSM by TE and 2D- SWE. One hundred and two 
had reliable LSM by TE and 88 had reliable LSM by 2D- SWE. The 
differences between the 88 patients with reliable LSM by 2D- SWE 
and the 16 patients without reliable LSM by 2D- SWE are shown in 
Table S1. Eighty- six patients had reliable LSM using both TE and 2D- 
SWE methods; a flowchart of patient inclusion and exclusion is pro-
vided in Figure S1. Baseline characteristics of the whole population 
and a comparison of the cohorts using TE and 2D- SWE are shown 
in Table 1.
The M probe and XL probe were used in 38.4% and 61.5% of 
patients respectively. Among XL probe patients, the BMI >30 kg/m2 
criteria was used in 92%, and the skin- to- capsule distance criteria 
≥25 mm was used in 8%. Technical failure to measure liver stiffness 
occurred in none of the cases with TE and in 15 of the cases (13%) with 
2D- SWE because of the inability to obtain an adequate signal for the 
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TA B L E  1  Baseline features of these 104 patients and the comparison of the cohorts using transient elastography (TE) and two- 
dimensional shear wave elastography (2D- SWE)
Characteristics Overall (n = 104) LSM by TE cohort (n = 102) LSM by 2D- SWE cohort (n = 88)
Age – y 53.4 ± 12.6 53.4 ± 12.6 53.2 ± 12.7
Sex, female, n (%) 43 (41.3) 43 (42.2) 33 (57.5)
BMI – kg/m2 30.9 ± 7.2 32.3 ± 7.2 31.6 ± 7.1
BMI – kg/m2, n (%)
<25 8 (7.6) 8 (9.3) 8 (9.4)
25- 29.9 37 (35.5) 32 (37.2) 32 (37.6)
≥30 59 (56.7) 47 (53.5) 45 (52.9)
Diabetes mellitus, n (%) 48 (47.1) 47 (46.1) 39 (44.3)
Arterial hypertension, n (%) 54 (52.0) 52 (51.0) 45 (51.0)
Dyslipidaemia, n (%) 54 (52.5) 53 (52.0) 45 (51.0)
ALT – IU/L 75.7 ± 45 80.7 ± 57.2 84.4 ± 58.4
AST – IU/L 63.7 ± 41.1 62.6 ± 40.2 65.0 ± 41.4
AST/ALT ratio 0.9 ± 0.4 0.9 ± 0.4 0.9 ± 0.4
Bilirubin – µmol/L 10.8 ± 6.9 10.6 ± 6.8 10.8 ± 6.4
GGT – IU/L 166 ± 240 164 ± 242 175 ± 258
Cholesterol – mmol/L 4.8 ± 1.21 4.8 ± 1.2 4.8 ± 1.20
HDL – mmol/L 1.1 ± 0.3 1.1 ± 0.3 1.1 ± 0.3
Triglycerides – mmol/L 2.2 ± 1.6 2.2 ± 1.6 2.2 ± 1.7
Glucose – mmol/L 6.3 ± 2.2 6.3 ± 2.2 6.2 ± 2.1
Insulin – mU/L 31.7 ± 29.1 31.7 ± 29.6 31.9 ± 31
Platelet count – g/L 220.8 ± 70.8 220 ± 70 223.4 ± 70.6
Albumin – g/L 38.8 ± 5.0 38 ± 4.9 38.7 ± 3.5
CAP value – (dB/m) 321.0 ± 47.6 320.3 ± 47.6 316.7 ± 46.8
LSM (TE) – kPa 11.9 ± 8.0 11.9 ± 7.9 11.1 ± 5.4
LSM (2D- SWE) – kPa 9.5 ± 4.4 9.5 ± 4.4 9.4 ± 4.3
Histology at biopsy
Steatosis grade
S0 (<5%) 0 (0) 0 (0) 0 (0)
S1 (5%- 33%) 27 (26.0) 27 (26.5) 19 (22.6)
S2 (34%- 66%) 31 (29.8) 29 (28.4) 29 (33.0)
S3 (>66%) 46 (44.2) 46 (45.1) 40 (45.5)
Steatosis % 55.3 ± 26.6 55.2 ± 26.8 57.3 ± 25.4
Activity
A0 9 (8.7) 9 (8.8) 8 (9.1)
A1 9 (8.7) 9 (8.8) 7 (8.0)
A2 63 (60.6) 61 (59.8) 55 (62.5)
A3 20 (19.2) 20 (19.6) 15 (17.0)
A4 3 (2.9) 3 (2.9) 3 (3.4)
Fibrosis stage
F0 11 (10.6) 11 (10.8) 10 (11.4)
F1 13 (12.5) 12 (11.8) 13 (14.8)
F2 35 (33.7) 35 (34.3) 29 (33.0)
F3 37 (35.6) 36 (35.4) 30 (34.1)
F4 8 (7.7) 8 (7.8) 6 (6.8)
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acquisitions. Unreliable LSM was observed in two cases (1.9%) with 
TE and in one case (0.9%) with 2D- SWE. Failure or unreliable results 
of LSM with 2D- SWE were associated with higher BMI (Spearman's 
correlation coefficient [ρ] = 0.32; 95%CI, 0.14- 0.49; P < .001), higher 
values of LSM by TE (ρ = 0.22; 95%CI, 0.03- 0.40; P = .02) and higher 
values of CAP (ρ = 0.21; 95%CI, 0.02- 0.39; P = .03).
LSM by TE and 2D- SWE was correlated with the histological 
fibrosis stage (Figure 1). Notably, the correlation of histological fi-
brosis stage with liver stiffness was stronger for 2D- SWE (ρ = 0.71; 
95%CI, 0.59- 0.79; P < .001) than for TE (ρ = 0.52; 95%CI, 0.37- 0.65; 
P < .001; Z = 2.21; P = .02). LSM by TE and 2D- SWE was strongly 
correlated with each other (ρ = 0.64; 95%CI, 0.50- 0.74; P < .001).
Characteristics Overall (n = 104) LSM by TE cohort (n = 102) LSM by 2D- SWE cohort (n = 88)
Ballooning stage
0 14 (13.5) 14 (13.7) 12 (13.6)
1 71 (68.3) 69 (67.6) 62 (70.5)
2 18 (17.3) 18 (17.6) 13 (14.8)
3 1 (1.0) 1 (1.0) 1 (1.1)
Lobular infiltration
0 12 (11.5) 12 (11.8) 10 (11.4)
1 82 (78.8) 80 (78.4) 71 (80.7)
2 10 (9.6) 10 (9.8) 7 (8.0)
NAS score
0- 2 13 (12.6) 13 (12.9) 10 (11.5)
3- 4 78 (75.7) 76 (75.2) 67 (77.0)
5- 8 12 (11.7) 12 (11.9) 10 (11.5)
Note: Data are given as mean ± standard deviation or as number of cases (percentage).
Abbreviations: ALT, alanine aminotransferase; BMI, body mass index; GGT, gamma- glutamyl transpeptidase; HDL, high- density lipoprotein; HOMA, 
homeostasis model assessment; IU, international units; kPa, kilopascal; y, years.
TA B L E  1  (Continued)
F I G U R E  1  Spearman's correlations 
for patient characteristics, liver histology, 
laboratory parameters and liver stiffness 
by two non- invasive tests (2D- SWE and 
TE). Of note, the correlation of histological 
fibrosis stage with liver stiffness was 
stronger for 2D- SWE than for TE. 
*P < .05; **P < .01
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Table 2 shows the diagnostic performance of LSM by TE cut- off 
values for fibrosis described recently by Eddows et al for NAFLD pa-
tients,11 namely 8.2, 9.7 and 13.6 kPa for each fibrosis stage F ≥ F2, 
F ≥ F3 and F = F4 respectively. LSM by TE had good sensitivity and 
specificity with a good PPV (0.88) for ≥F2 and an excellent NPV 
(0.98) for F4. The discriminative capacity between F0- F2 vs F3 was 
lower with an AUROC of 0.72 (0.63- 0.82) at a threshold of 9.7 kPa. 
False negative rate of LSM by TE for significant fibrosis (≥F2) was 
16%. The diagnostic performance of LSM by 2D- SWE using the 
cut- off proposed for NAFLD patients20 is also detailed in Table 2. 
It showed good diagnostic performance for fibrosis stages F ≥ F2 
and F = F4. The discriminative ability of LSM by 2D- SWE was nu-
merically higher than by TE for distinguishing F0- F2 vs F3 with an 
AUROC of 0.84 (0.76- 0.92) at a threshold of 9.2 kPa.
The AUROC and false positive rate for LSM by TE and 2D- SWE 
for diagnosing histological fibrosis stage according to the histologi-
cal inflammatory activity stage are summarized in Table S2.
3.2  |  Potential confounders of the association 
between fibrosis and liver stiffness measured by 
TE and 2D- SWE
We calculated a baseline linear regression model of the fibrosis stage 
on the LSM. To assess whether the histological steatosis, inflamma-
tory activity, NAS score and laboratory parameters would influence 
the association between fibrosis and LSM by TE or 2D- SWE, we 
compared all further models against this baseline model.
3.2.1  |  Influence of inflammation and steatosis on 
LSM by TE
The fibrosis stage on histology explained 35% of the variance of LSM 
by TE (P < .001). The variance explained by the model did not increase 
significantly compared to the baseline model after including the main 
effect of steatosis percentage and the interaction of steatosis percent-
age and fibrosis stage (R2
cha
 = .04; P = 1) (Table 3). When including in-
flammatory activity and the interaction between inflammatory activity 
and histological fibrosis stage, the model explained 25% more variance 
in LSM by TE (P < .01). After controlling for fibrosis, age, sex and BMI, 
both the main effect of inflammatory activity (P < .001) and the in-
teraction effect between inflammatory activity and fibrosis (P = .01) 
remained significantly associated with LSM by TE, and independently 
explained 11% and 13% of variance in LSM by TE respectively (Table 4). 
This indicates that the strength of the association between fibrosis on 
histology and LSM by TE changes according to the severity of the in-
flammatory activity. This effect is visualized in Figure 2. Regression 
results for the individual combinations of fibrosis stage and grade of 
inflammatory activity are provided in Tables S3 and S4.
Furthermore, we tested whether the variance explained by the 
fibrosis stage would be increased by including individual inflamma-
tory activity components (ballooning and lobular Infiltration), NAS 
score, M30, ratio of AST/ALT, CAP or their interaction. None of 
these models showed a significant increase in the explained variance 
(Table S5), suggesting that the strength of the association between 
liver fibrosis and LSM is mostly modified by the overall severity of 
inflammation.
3.2.2  |  Influence of inflammation and steatosis on 
LSM by 2D- SWE
The same analysis was applied to LSM by 2D- SWE as the dependent 
variable. In the baseline model, fibrosis stage on histology explained 
52% in variance of LSM by 2D- SWE (P < .001). Including steatosis per-
centage and its interaction with fibrosis stage into the model did not 
significantly improve the model (R2
cha
 = .00; P = 1). Similarly, including 
inflammatory activity and its interaction with fibrosis stage did not 
explain significantly more variance than the baseline model (R2
cha
 = .06; 
P = 1) (Table 3). We tested the same additional models as for LSM by 
2D- SWE. None of these models explained significantly more variance 
in the dependent variable, indicating that none of the variables altered 
the effect of the fibrosis stage on LSM by 2D- SWE (Table S5).
3.3  |  Sensitivity analysis in patients with reliable 
LSM using both TE and 2D- SWE methods
The analysis of the 86 patients with reliable LSM on both TE and 
2D- SWE showed similar results. Inflammatory activity and its 
TA B L E  2  Diagnostic performance of LSM by TE and 2D- SWE for 
each fibrosis stage
LSM by TE
F ≥ F2 F ≥ F3 F = F4
AUROC (95%CI) 0.76 (0.64- 0.88) 0.72 (0.63- 0.82) 0.89 (0.78- 1.00)
Cut- off (kPa) 8.2 9.7 13.6
Se (95%CI) 0.83 (0.75- 0.89) 0.73 (0.64- 0.81) 0.87 (0.79- 0.92)
Sp (95%CI) 0.62 (0.52- 0.71) 0.53 (0.43- 0.62) 0.77 (0.68- 0.84)
PPV (95%CI) 0.88 (0.80- 0.93) 0.55 (0.46- 0.64) 0.24 (0.16- 0.33)
NPV (95%CI) 0.53 (0.44- 0.62) 0.72 (0.62- 0.79) 0.98 (0.94- 0.99)
FPR (95%CI) 0.37 (0.28- 0.47) 0.46 (0.37- 0.56) 0.22 (0.15- 0.31)
FNR (95%CI) 0.16 (0.10- 0.24) 0.26 (0.18- 0.35) 0.12 (0.07- 0.20)
LSM by 2D- SWE
AUROC (95%CI) 0.83 (0.72- 0.93) 0.84 (0.76- 0.92) 0.94 (0.89- 0.99)
Cut- off (kPa) 7.1 9.2 13
Se (95%CI) 0.86 (0.79- 0.91) 0.65 (0.64- 0.81) 0.83 (0.75- 0.89)
Sp (95%CI) 0.73 (0.64- 0.81) 0.86 (0.78- 0.91) 0.87 (0.80- 0.92)
PPV (95%CI) 0.90 (0.83- 0.94) 0.78 (0.69- 0.84) 0.33 (0.25- 0.42)
NPV (95%CI) 0.65 (0.55- 0.73) 0.77 (0.62- 0.79) 0.98 (0.94- 0.99)
FPR (95%CI) 0.26 (0.18- 0.35) 0.13 (0.08- 0.21) 0.33 (0.25- 0.42)
FNR (95%CI) 0.13 (0.08- 0.21) 0.34 (0.25- 0.43) 0.16 (0.10- 0.24)
Abbreviations: FNR, false negative rate; FPR, false positive rate; NPV, 
negative predictive value; PPV, positive predictive value; Se, sensitivity; 
Sp, specificity.
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interaction with fibrosis stage explained 27% in the variance of LSM 
by TE (P < .01). Fibrosis stage, inflammatory activity and its interac-
tion with liver fibrosis remained significant when controlling for age, 
BMI and sex. Similar to the larger data set, none of the models in 
which LSM by 2D- SWE was tested as the dependent variable im-
proved the baseline model significantly. Table S6 contains the model 
comparisons for this sensitivity analysis.
4  |  DISCUSSION
In this prospective cohort study, we found that inflammatory activ-
ity assessed on histology significantly affects liver stiffness meas-
ured by TE, but not liver stiffness measured by 2D- SWE in patients 
with NAFLD. The severity of steatosis on histology did not affect the 
association between LSM and fibrosis by any of the two elastogra-
phy methods used. In our cohort, LSM by 2D- SWE reflects liver fi-
brosis more accurately than LSM by TE in NAFLD patients. However, 
LSM failures were more frequent using 2D- SWE than TE owing to 
the technical limitations – mostly because of obesity likely impeding 
an efficient transmission of the ultrasound waves to the liver.
It has been reported that 2D- SWE has a higher rate of fail-
ure in patients with high BMI.21 This is likely the reason why we 
experienced a relatively high rate of 2D- SWE failures in our cohort 
composed mostly of overweight and obese patients. Nevertheless, 
the 13% failure rate of LSM by 2D- SWE is in agreement with that re-
ported in the study by Cassinotto et al.15 In addition, in our study, we 
found a lower unreliable/failure rate of LSM by TE than previously 
reported (1.9% vs 14%), likely because the XL probe was available 
for patients with obesity and/or skin- to- capsule distance ≥25 mm. 
Our findings are in keeping with studies using XL probe, which have 
reported a high rate of LSM success with TE (97% of patients could 
be evaluated successfully).11,22
The diagnostic performance of LSM by TE and by 2D- SWE for 
fibrosis stages in this study is also in line with data from large co-
horts.11,20 Our results are in agreement with the previous data by 
Cassinotto et al regarding a lack of influence of steatosis and inflam-
matory activity on LSM by 2D- SWE, and confirm that LSM by 2D- 
SWE is accurate in predicting fibrosis in NAFLD patients. Consistent 
with previous reports,10- 12 we found that steatosis did not affect 
LSM by TE. We could not confirm the association between steatosis 
and liver stiffness supported by the study by Petta et al,13 which, 
however, used exclusively the M probe, suggesting a potential tech-
nical error as a result of inappropriate elastography frequency. Our 
results are similar to those shown in recent cohorts,11,12 in which M 
and XL probes were used. For example, Wong et al12 used M and 
Outcome LSM by TE LSM by 2D- SWE
Model F (df) R2
cha
P- value F (df) R2
cha
P- value
Baseline: Fibrosis 
stage
12.81 (4, 85) .35 <.001 22.15 (4, 81) .52 <.001
+Steatosis (%), 
interaction
1.25 (5, 88) .04 1 0.15 (5, 74) .00 1
+Inflammatory 
activity, 
interaction
3.56 (20, 81) .25 <.01 0.78 (20, 68) .06 1
Note: P- values Holm- adjusted for multiple comparisons. F is the ratio of explained variance 
between the baseline model and those with added predictors.
TA B L E  3  Model comparisons against 
the baseline model with fibrosis stage on 
the liver stiffness measurement (LSM) 
by transient elastography (TE) and by 
two- dimensional shear wave elastography 
(2D- SWE)
TA B L E  4  Logistic regression models with liver stiffness measurement (LSM) by transient elastography (TE) as the dependent variable
Predictor (df)
Model 1 Model 2 Model 3
F η2 P- value F η2 P- value F η2 P- value
Fibrosis stage (4) 12.81 0.37 <.001 17.54 0.35 <.001 18.36 0.35 <.001
Inflammatory 
activity (4)
5.76 0.11 <.001 6.04 0.11 <.001
Inflammatory 
activity
2.68 0.13 <.01 2.70 0.13 <.01
Fibrosis score (10)
Age (1) 4.32 0.02 .03
BMI (1) 3.69 0.02 .05
Gender (1) 0.95 0.00 .33
Residual df 95 81 77
R2 (95%CI) .35 (.20; .49) .59 (.23; .70) .63 (.50; .73)
Note: All models were fit to m = 20 multiply imputed data sets based on 102 patients with reliable LSM by TE.
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XL probes in patients with BMI <30 and ≥30 kg/m2, respectively, 
similar to our criteria, showing that hepatic steatosis did not affect 
the performance of LSM by TE. Therefore, studies using only the M 
probe are likely to give an incorrect interpretation in many patients 
with NAFLD.
The liver is a visco- elastic structure. Most of the ultrasound 
elastography methods implement a simple linear elastic model that 
quantifies the tissue elasticity but not the liver viscosity, which has 
been associated with necro- inflammatory activity.23 Recent experi-
mental23 and clinical24 studies showed that LSM assessment using 
2D- SWE method reflects elasticity but does not reflect viscosity. 
Our results are in line with this observation, and suggest that while 
liver stiffness measured by TE allows an overall assessment of visco- 
elastic properties of the liver tissue, it is more susceptible to the 
confounding effect of inflammation as compared to methods purely 
designed to reflect the liver elastic properties such as 2D- SWE. New 
techniques known as shear wave dispersion imaging24 and shave 
wave spectrometry25 have been proposed to measure viscosity by 
analysing dispersion properties of the wave propagation in the tis-
sue.26 To what extent, however, viscosity and elasticity can truly be 
differentiated is matter of debate, since they are correlated.25
Interestingly, Petta et al13 reported that inflammation was an in-
dependent predictor of a higher LSM by TE (P < .001). Our study 
further expands these previous findings supporting that not only 
inflammation, but also the interaction between inflammatory activ-
ity and fibrosis affects the reliability of LSM by TE on fibrosis as-
sessment in NAFLD. This may be interpreted as a limitation of TE 
for fibrosis assessment in NAFLD. The combination of unrelated 
non- invasive methods to predict fibrosis has emerged to overcome 
the limitation of individual tests. In fact, in NAFLD patients, recent 
studies found that the combination or sequential use of a second 
elastography technique or serum- based tests improves the predic-
tive ability for fibrosis.27,28
On the other hand, non- invasive tests identifying inflammation 
in NAFLD are lacking. Since inflammation seems to increase LSM 
using TE but not using 2D- SWE, one could hypothesize that combin-
ing both TE and 2D- SWE could help identify those patients in whom 
inflammation is present, namely those showing a higher LSM by TE 
compared to 2D- SWE. This would have particular relevance when 
considering that the NAFLD field is seeking a non- invasive test that 
identifies patients with fibrosis and clinically active NASH suitable 
for clinical trials on novel therapies, and could be object of the future 
studies.
This study has limitations. Some of them are inherent to liver 
biopsies, such as sampling error and interobserver variability.8 We 
strived to overcome this by following the specific quality criteria 
(length of sample; interpretation from an expert liver pathologist) 
and using predefined histological scoring systems. Another limita-
tion was related to the heterogeneous distribution of cases in the 
different subgroups of histological fibrosis and steatosis or inflam-
mation, which resulted in a low number of cases in some subgroups. 
Therefore, to avoid misleading results, we refrained from performing 
subgroup analysis of these combinations and instead focused on the 
global effects of the predictors. Not all patients had valid LSM using 
F I G U R E  2  Boxplot of liver stiffness measurement (LSM) in patients with non- alcoholic fatty liver disease using transient elastography 
(TE) and two- dimensional shear wave elastography (2D- SWE) by fibrosis stage and inflammatory activity. When using TE, the association of 
histological fibrosis and LSM changes according to the level of inflammatory activity
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both elastography techniques, leading to a possible bias in the in-
terpretation of the results; however, sensitivity analysis on patients 
with valid measurements in both techniques confirmed the findings 
of the overall cohort.
There are several strengths of this study. The population is a 
well- characterized prospective cohort in whom the use of the op-
timal TE probe (either M or XL) was used to characterize NAFLD. 
Moreover, the statistical analysis is done using a principled approach 
where predictors are tested against a meaningful baseline model 
rather than a simple null model. This has the advantage of adding 
explanatory weight to observed phenomena, while fully utilizing the 
limited available data.
In summary, we found that in NAFLD patients, the association 
between fibrosis and liver stiffness using 2D- SWE is not altered by 
steatosis and inflammatory activity. Furthermore, LSM by 2D- SWE 
was better correlated with the fibrosis stage. On the other hand, 
liver fibrosis assessment by LSM using TE was also not affected by 
steatosis, but it was affected by the histological degree of inflam-
matory activity and its interaction with fibrosis, which would result 
in an over interpretation of liver fibrosis. According to our data, we 
conclude that liver stiffness by 2D- SWE appears to reflect fibrosis 
more accurately in patients with NAFLD when technically feasible.
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